Search

Your search keyword '"Sanson, Marc"' showing total 111 results

Search Constraints

Start Over You searched for: Author "Sanson, Marc" Remove constraint Author: "Sanson, Marc" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
111 results on '"Sanson, Marc"'

Search Results

1. Supplementary Tables S1-S3 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

2. Supplementary Figure S1. from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

3. Supplementary Figure S7 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

4. Supplementary Figure S3 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

5. Supplementary Figure S2 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

6. Supplementary Figure S5 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

7. Supplementary Figure S4 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

8. Supplementary Tables S1-S3 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

9. Supplementary Figure S3 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

10. Data from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

11. Supplementary Figure S2 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

12. Data from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

13. Supplementary Figure S1. from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

14. Supplementary Figure S6 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

15. Supplementary Figure S5 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

16. Supplementary Figure S7 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

17. Supplementary Figure S8 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

18. Supplementary Figure S6 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

19. Supplementary Figure S4 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

20. Supplementary Figure S8 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

21. Supplementary Methods, Tables, and Figure from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

22. Data from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

23. Supplementary Methods, Tables, and Figure from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

24. Data from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

25. S1: Genetic landscape of MDM2/TP53 pathway. from Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas

26. S7: Additional material and methods from Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas

27. Supplementary Table 7 from Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma

28. Figure S2 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial

29. Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

30. Supplementary Figure 5 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

31. S5: MDM2, MDM4 and TP53 gene expression in the GBM cell lines of cohort #1 as determined by RT-qPCR. from Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas

32. Figure S1 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial

33. Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

34. Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

35. Supplementary Table 5 from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

36. Supplementary Figure Legend from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

37. Supplementary Figure 2 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

38. Supplementary Table 5 from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

39. S3: Evolution of MDM2 and TP53 status over time of 5 patients affected by MDM2-amplified GBM. from Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas

40. Figure S3 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial

41. Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

42. Supplementary Figure 1 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

43. Figure S2 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial

44. Supplementary Tables from Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma

45. Data from Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma

46. Table S2 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial

47. S7: Additional material and methods from Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas

48. Supplementary Figure 6 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

49. Supplementary Figure 3 from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

50. Data from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Catalog

Books, media, physical & digital resources